Literature DB >> 17172408

Glucocorticoid receptor transcriptional isoforms and resistance in multiple myeloma cells.

Beatriz Sánchez-Vega1, Nancy Krett, Steven T Rosen, Varsha Gandhi.   

Abstract

Although glucocorticoids play an important role in the treatment of multiple myeloma, some patients do not respond or develop resistance. The glucocorticoid receptor (GR), a single gene, mediates the effects of glucocorticoids. Using a model system of a multiple myeloma cell line sensitive to glucocorticoids and its early and late resistant variants, we have analyzed mutations in the GR gene, detected the presence of different transcriptional isoforms, quantified their levels of expression, and identified the promoters that regulate their expression. Levels of GR transcripts were comparable with the expression of total GR protein. Development of resistance correlates with an overall reduction in GR mRNA levels. This decrease in GR levels is neither due to mutation of the gene nor due to methylation. GRalpha is the predominant isoform in the sensitive cell line decreasing in expression in the early resistant cells and virtually undetectable in late resistant cells. GR-P is expressed at equivalent levels in both sensitive and early resistant cells, whereas in the late resistant cells, GR-P is the predominant isoform. GR-A is only expressed in the early resistant cell line. GRbeta is the least expressed isoform in all cell lines. Interestingly, the level of expression of exon 1-exon 2 RNA fragments remains similar in sensitive and resistant cell lines. Resistant cells became sensitive to glucocorticoids after GRalpha transfection. In conclusion, we show different patterns of expression of the GR isoforms and provide evidence that a decline in the expression of GRalpha may be associated with development of resistance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17172408     DOI: 10.1158/1535-7163.MCT-06-0344

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  17 in total

1.  Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression.

Authors:  Zachary J Walker; Michael J VanWyngarden; Brett M Stevens; Diana Abbott; Andrew Hammes; Christophe Langouët-Astrie; Clayton A Smith; Brent E Palmer; Peter A Forsberg; Tomer M Mark; Craig T Jordan; Daniel W Sherbenou
Journal:  Blood Adv       Date:  2020-04-28

2.  Glucocorticoid resistance in a multiple myeloma cell line is regulated by a transcription elongation block in the glucocorticoid receptor gene (NR3C1).

Authors:  Beatriz Sánchez-Vega; Varsha Gandhi
Journal:  Br J Haematol       Date:  2008-12-26       Impact factor: 6.998

3.  Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors.

Authors:  Sanjai Sharma; Alan Lichtenstein
Journal:  Blood       Date:  2008-05-30       Impact factor: 22.113

4.  Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma.

Authors:  Francis Robert; William Roman; Alexandre Bramoullé; Christof Fellmann; Anne Roulston; Chaim Shustik; John A Porco; Gordon C Shore; Michael Sebag; Jerry Pelletier
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-02       Impact factor: 11.205

5.  Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1.

Authors:  Christoph J Heuck; Jackie Szymonifka; Emily Hansen; John D Shaughnessy; Saad Z Usmani; Frits van Rhee; Elias Anaissie; Bijay Nair; Sarah Waheed; Yazan Alsayed; Nathan Petty; Clyde Bailey; Joshua Epstein; Antje Hoering; John Crowley; Bart Barlogie
Journal:  Clin Cancer Res       Date:  2012-08-01       Impact factor: 12.531

6.  Lack of mutations in the gene coding for the hGR (NR3C1) in a pediatric patient with ACTH-secreting pituitary adenoma, absence of stigmata of Cushing's syndrome and unusual histologic features.

Authors:  George Briassoulis; Anelia Horvath; Paola Christoforou; Maya Lodish; Paraskevi Xekouki; Martha Quezado; Nicholas Patronas; Meg F Keil; Constantine A Stratakis
Journal:  J Pediatr Endocrinol Metab       Date:  2012       Impact factor: 1.634

7.  Ectopic microRNA-150-5p transcription sensitizes glucocorticoid therapy response in MM1S multiple myeloma cells but fails to overcome hormone therapy resistance in MM1R cells.

Authors:  Ajay Palagani; Ken Op de Beeck; Stefan Naulaerts; Jolien Diddens; Chandra Sekhar Chirumamilla; Guy Van Camp; Kris Laukens; Karen Heyninck; Sarah Gerlo; Pieter Mestdagh; Joke Vandesompele; Wim Vanden Berghe
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

Review 8.  Endothelial Response to Glucocorticoids in Inflammatory Diseases.

Authors:  Karolina A Zielińska; Laura Van Moortel; Ghislain Opdenakker; Karolien De Bosscher; Philippe E Van den Steen
Journal:  Front Immunol       Date:  2016-12-14       Impact factor: 7.561

9.  Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing.

Authors:  Muntasir Mamun Majumder; Raija Silvennoinen; Pekka Anttila; David Tamborero; Samuli Eldfors; Bhagwan Yadav; Riikka Karjalainen; Heikki Kuusanmäki; Juha Lievonen; Alun Parsons; Minna Suvela; Esa Jantunen; Kimmo Porkka; Caroline A Heckman
Journal:  Oncotarget       Date:  2017-05-05

10.  Differential expression of placental glucocorticoid receptors and growth arrest-specific transcript 5 in term and preterm pregnancies: evidence for involvement of maternal stress.

Authors:  D Mparmpakas; E Zachariades; G Sotiriadis; A Goumenou; A J Harvey; Y Gidron; E Karteris
Journal:  Obstet Gynecol Int       Date:  2014-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.